• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The future of fulvestrant ("Faslodex").

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Affiliation
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. anthony.howell@christie-tr.nwest.nhs.uk
    Issue Date
    2005
    
    Metadata
    Show full item record
    Abstract
    Changes in clinical practice regarding favoured first-line and adjuvant treatments for postmenopausal women with advanced breast cancer (ABC) mean that it is becoming increasingly important to identify agents that are effective following aromatase inhibitor (AI) failure as well as tamoxifen failure. Fulvestrant ("Faslodex") is a new oestrogen receptor (ER) antagonist with no agonist effects that binds, blocks and degrades the ER. Fulvestrant is at least as effective as anastrozole following tamoxifen failure and also shows activity after progression on AIs. Its very good tolerability profile and novel mode of action, might offer potential for the use of fulvestrant in combination regimens, and there is also scope for investigating the use of loading and higher dose regimens in an attempt to further enhance efficacy. Here, the rationale and evidence for the efficacy of fulvestrant following AI failure and its combination with AIs and novel agents such as gefitinib and trastuzumab will be reviewed. The ongoing clinical development programme for fulvestrant will more fully the role of this valuable new agent in the treatment of postmenopausal ABC.
    Citation
    The future of fulvestrant ("Faslodex"). 2005, 31 Suppl 2:S26-33 Cancer Treat. Rev.
    Journal
    Cancer Treatment Reviews
    URI
    http://hdl.handle.net/10541/74918
    DOI
    10.1016/j.ctrv.2005.08.007
    PubMed ID
    16198056
    Type
    Article
    Language
    en
    ISSN
    0305-7372
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ctrv.2005.08.007
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    • Authors: Howell A
    • Issue date: 2006 Mar
    • Clinical development of fulvestrant ("Faslodex").
    • Authors: Howell A, Abram P
    • Issue date: 2005
    • Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    • Authors: Gradishar W
    • Issue date: 2005 Jun
    • Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    • Authors: Oakman C, Moretti E, Santarpia L, Di Leo A
    • Issue date: 2011 Feb
    • Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    • Authors: Bundred N
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.